Ataluren C₁₅H₉FN₂O₃

Therapeutic indications

Ataluren is indicated for:

Duchenne muscular dystrophy

Population group: both men and women, only infants (40 days - 1 year old) , children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Ataluren is indicated for the treatment of Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene, in ambulatory patients aged 2 years and older.

The presence of a nonsense mutation in the dystrophin gene should be determined by genetic testing.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

10 mg/kg body weight in the morning, 10 mg/kg body weight at midday and 20 mg/kg body weight in the evening

Contraindications

Ataluren is contraindicated in the following cases:

Lactation

Pregnancy

Severe renal impairment, end-stage renal disease

at least one of

Renal failure stage 5: Kidney failure (GFR <15 mL/min/1.73 m2 or dialysis)

Intravenous aminoglycosides

Aminoglycoside antibacterials

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.